Textbook of Digital Health

Introduction

Digital therapeutics are software programmes that deliver evidence-based therapeutic interventions to prevent, manage, or treat medical conditions (Dang et al., 2020). Unlike wellness apps that provide general health support, digital therapeutics undergo clinical validation and regulatory review to demonstrate safety and effectiveness for specific conditions. The field has shown genuine clinical promise - particularly for insomnia, substance use disorders, and diabetes management - but has also experienced significant commercial turbulence, with several pioneering companies failing despite strong evidence for their products.

This chapter explores digital therapeutics including definitions and classification, regulatory pathways, clinical evidence requirements, therapeutic applications, and the evolving business model. The gap between clinical efficacy and commercial viability is a recurring theme, and one that shapes how healthcare professionals should think about this treatment category.

Defining Digital Therapeutics

In 2017, when the FDA cleared the first prescription digital therapeutic for substance use disorder, it marked an important milestone. Software had officially crossed the threshold from wellness tool to regulated medical treatment. But what exactly separates a digital therapeutic from the thousands of health apps available in consumer app stores?

The distinction lies in the burden of proof. A meditation app might help users feel calmer, and its marketing can make general wellness claims without restriction. A digital therapeutic treating anxiety disorder, by contrast, must demonstrate through clinical trials that it produces measurable improvements in patients with diagnosed conditions. The Digital Therapeutics Alliance (DTA), which served as the industry's standard-setting body, codified this distinction: digital therapeutics must deliver actual medical interventions backed by clinical evidence, not merely information or support. The DTA significantly reduced its activities through 2023-2024 amid the sector's commercial difficulties, and in March 2025 was acquired by ATA Action - the advocacy arm of the American Telemedicine Association - which folded its work into a new Advancing Digital Health Coalition (ATA Action, 2025). The DTA's definitional framework remains widely referenced (Digital Therapeutics Alliance, 2024), and the Digital Medicine Society (DiMe) has assumed a more prominent role in advancing standards for the field (Digital Medicine Society, 2024).

Consider the difference in practice. A diabetes wellness app might track blood glucose readings and offer general tips about healthy eating. A digital therapeutic for diabetes, however, delivers a validated behavioural intervention programme that trials have shown to reduce HbA1c levels. One informs; the other treats. This distinction carries regulatory consequences: digital therapeutics must achieve appropriate clearance or approval, and their marketing claims must align precisely with their clinical evidence.

The field divides further based on how these interventions reach patients. Some digital therapeutics require prescriptions, integrating into clinical workflows alongside medications and procedures. Others meet the same evidence and regulatory standards but are available directly to consumers, expanding access beyond traditional healthcare gatekeepers. This variation reflects the diversity of conditions treated and the healthcare systems in which digital therapeutics operate.

What makes these software programmes therapeutic? The mechanisms vary as widely as the conditions they address. Some deliver structured psychological interventions. A cognitive behavioural therapy programme for insomnia, for example, guides patients through sleep restriction protocols and cognitive restructuring exercises that were once available only from a trained therapist. Others harness gamification to drive neurological change, engaging patients in carefully designed challenges that strengthen attention networks or retrain movement patterns. Still others combine education, real-time coaching, and behavioural reinforcement to help patients with chronic conditions develop lasting self-management skills. The common thread is not the mechanism but the evidence: each must prove it works for the specific condition it claims to treat.

Clinical Evidence Requirements

If digital therapeutics claim to treat disease, they must be held to the same evidentiary standards as other treatments. In practice, this means randomised controlled trials, peer-reviewed publication, and regulatory scrutiny - though the specific requirements vary by pathway and jurisdiction.

Randomised controlled trials are the gold standard for establishing digital therapeutic effectiveness. Participants are randomly assigned to receive the digital therapeutic or a control condition, with outcomes compared between groups. Well-designed trials control for placebo effects and demonstrate that observed benefits result from the intervention itself.

Control conditions in digital therapeutic trials present design challenges. Sham software that provides an equivalent user experience without active therapeutic content is a placebo analogue. Wait-list controls, treatment-as-usual comparisons, and active comparator designs offer alternatives depending on research questions. The interactive nature of digital therapeutics makes true blinding difficult, as participants typically recognise whether they are receiving an engaging intervention.

Outcome measures must capture clinically meaningful endpoints: symptom reduction, functional improvement, quality of life, and disease markers such as HbA1c or validated symptom scores. Digital biomarkers derived from user interaction data (changes in response times, completion rates, or interaction patterns) offer novel measurement approaches, though their correlation with clinical outcomes requires its own validation. Trials must also capture durability of benefit. Many digital therapeutics deliver time-limited interventions (a twelve-week CBT programme, for instance), so trials must assess not only immediate effects but whether improvements persist after active treatment concludes.

Table 7.1: Digital Therapeutics Clinical Trial Design

Evidence quality varies across digital therapeutics products. Some have robust trial data published in peer-reviewed journals. Others have limited evidence that may not generalise beyond study populations. Healthcare providers should evaluate evidence critically when considering digital therapeutic prescriptions.

Regulatory Pathways

When software claims to treat disease, regulators face a fundamental challenge: frameworks designed for pills, devices, and procedures must accommodate interventions that exist as code. The global regulatory response has been largely consistent in principle: therapeutic software is a medical device requiring evidence of safety and effectiveness (IMDRF, 2017). However, implementation varies considerably across jurisdictions, creating both opportunities and challenges for companies seeking global markets.

United States

The FDA chose to regulate digital therapeutics through its existing medical device pathways rather than creating an entirely new framework. This pragmatic approach enabled faster market entry but required creative adaptation of rules designed for physical objects.

The key moment came in 2017 when the first prescription digital therapeutic for substance use disorder sought clearance. No substantially equivalent device existed (no "predicate" in FDA parlance), so the company navigated the De Novo pathway, designed for novel low-to-moderate risk devices. Success meant more than just clearance for one product; it established an entire new device classification that subsequent digital therapeutics could reference. This first-mover created a regulatory precedent that shaped the field.

Once a De Novo clearance establishes a classification, subsequent digital therapeutics targeting similar conditions can pursue the faster 510(k) pathway by demonstrating substantial equivalence to the cleared predicate. The difference is notable: De Novo submissions require comprehensive safety and effectiveness data, while 510(k) clearances can rely more heavily on the established predicate, reducing development timelines and costs.

The FDA has also created accelerated pathways recognising digital therapeutics' potential. The Breakthrough Devices Program offers more intensive agency engagement during development for products addressing serious conditions with significant advantages over existing treatments. Several digital therapeutics have earned this designation, gaining access to iterative feedback that helps developers anticipate and address regulatory concerns before formal submission.

United Kingdom

Brexit forced the UK to establish independent regulatory arrangements after decades operating within the European framework. The MHRA now regulates digital therapeutics as software medical devices under UK Medical Devices Regulations, classifying most as Class I or IIa based on their intended purpose and risk profile. The transition from CE to UKCA marking has been repeatedly extended, and manufacturers continue to navigate parallel UK and EU requirements. For digital therapeutic developers, this means potentially pursuing separate regulatory clearances for markets that once operated under unified rules.

European Union

The EU Medical Device Regulation provides the overarching framework, requiring clinical evidence and conformity assessment through notified bodies. Most therapeutic software falls into Class IIa or higher, necessitating third-party review.

But within this framework, individual member states have pioneered innovative approaches. Germany's DiGA pathway is perhaps the most comprehensive national framework for digital therapeutics globally. The Federal Institute for Drugs and Medical Devices (BfArM) evaluates applications against criteria spanning data security, interoperability, and demonstrated healthcare benefits. The key innovation is that approved DiGAs become automatically reimbursable through statutory health insurance, providing the commercial certainty that has eluded digital therapeutics in other markets. Physicians can prescribe DiGAs knowing patients will have coverage, removing a barrier that has hampered adoption elsewhere.

However, the DiGA pathway has evolved to require stronger evidence over time. Products initially listed on a provisional basis must demonstrate positive care effects through comparative studies to achieve permanent listing. In 2023-2024, several digital therapeutics were delisted from the DiGA directory after failing to provide sufficient evidence of benefit within the required timeframe.

France and Belgium have developed similar frameworks, recognising that regulatory clearance without reimbursement leaves patients unable to access treatments their doctors want to prescribe.

Other Jurisdictions

Internationally, regulatory approaches continue developing along parallel tracks. Health Canada and Australia's TGA have established frameworks aligned with international principles for software-based medical devices. Japan and South Korea have issued specific guidance reflecting their healthcare systems' particular characteristics. The common thread is recognition that therapeutic software requires regulatory oversight; the variations lie in evidence requirements, classification systems, and notably, the connection between regulatory approval and patient access through reimbursement. Companies seeking global reach must navigate a complex matrix of requirements, often conducting additional studies or adapting products to meet jurisdiction-specific standards.

Table 7.2: Digital Therapeutics Regulatory Frameworks

Therapeutic Applications

The conditions that digital therapeutics address share a common characteristic: they respond to interventions that require sustained patient engagement rather than passive receipt of treatment (Wang et al., 2023). This explains why behavioural health led the field and why chronic disease management has followed closely behind.

Addiction Treatment

The story of digital therapeutics in substance use disorder illustrates both the promise and the difficulties of this field. When Pear Therapeutics secured FDA clearance for reSET in 2017, it validated an important idea: software could deliver cognitive behavioural therapy with sufficient rigour to qualify as a regulated treatment. Clinical trials demonstrated that patients receiving the digital therapeutic alongside standard outpatient treatment achieved higher abstinence rates than those receiving standard treatment alone.

Yet the commercial outcome was sobering. Despite strong clinical evidence and regulatory success, Pear Therapeutics filed for bankruptcy in 2023. The company had solved the scientific and regulatory challenges but stumbled on the commercial ones. Achieving sustainable reimbursement and driving adoption proved more difficult than proving the treatment worked. This cautionary tale echoes through the digital therapeutics industry: clinical efficacy is necessary but not sufficient for success. The evidence supporting these interventions remains valid, but the business model challenges have prompted the entire sector to reconsider paths to sustainability.

Insomnia

Cognitive behavioural therapy for insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia, but the recommendation has long outpaced availability. Training a therapist to deliver CBT-I takes months; a patient waiting for treatment might wait just as long. Digital therapeutics addressed this gap by encoding CBT-I protocols into structured programmes that guide patients through sleep restriction, stimulus control, sleep hygiene, and cognitive restructuring.

The clinical results have been encouraging. Multiple FDA-cleared products have demonstrated outcomes comparable to therapist-delivered treatment in randomised trials. Big Health's prescription product SleepioRx received FDA clearance for chronic insomnia in August 2024 (Big Health, 2024), building on a decade of evidence from the existing Sleepio digital care programme (the company also offers Daylight for generalised anxiety disorder). For patients who previously had no practical access to CBT-I (because of geographic isolation, cost, or simply insufficient local therapists), digital therapeutics converted a theoretical treatment recommendation into an accessible option.

Mental Health

The mental health treatment gap is one of healthcare's most pressing challenges. Millions of people with diagnosable depression, anxiety, or PTSD cannot access evidence-based treatment because there simply are not enough qualified providers. Waiting lists stretch for months; in many areas, specialised care is entirely unavailable.

Digital therapeutics offer a partial solution by delivering structured psychological interventions without requiring a therapist for every session. Many patients still benefit from therapeutic relationships, and digital therapeutics can extend treatment access to those who would otherwise receive nothing. A patient on a six-month waiting list for a therapist might begin evidence-based treatment immediately through a digital therapeutic, potentially achieving improvement before a traditional appointment becomes available.

Chronic Disease

Managing diabetes, hypertension, and cardiovascular disease requires patients to sustain behavioural changes (in diet, exercise, medication adherence, and monitoring) over years and decades. Traditional healthcare encounters, however valuable, occur too infrequently to provide the ongoing support many patients need.

Digital therapeutics for chronic disease management fill this gap through continuous engagement. A diabetes management application might integrate with a connected glucose monitor, analysing patterns and delivering personalised guidance between clinical visits. The intervention is not merely informational; clinical trials validate that these programmes produce measurable improvements in disease markers. The software becomes a persistent treatment companion in ways that episodic clinical encounters cannot match.

Paediatric Conditions

When Akili Interactive's EndeavorRx received FDA clearance for paediatric ADHD in 2020, it marked a novel milestone: a video game approved as a prescription treatment. The approach recognised that children engage differently than adults, and that engagement is central to therapeutic effect.

The underlying science involves targeted cognitive training designed to strengthen attention networks through carefully calibrated challenges embedded within gameplay. Children experience an engaging game; their brains receive structured cognitive exercise. Clinical trials demonstrated measurable improvements in attention, validating that the game-based delivery mechanism could produce therapeutic benefits.

However, the EndeavorRx story also illustrates the commercial fragility of the DTx sector. Akili Interactive was acquired by Virtual Therapeutics in mid-2024 (merger announced May 2024, completed July 2024) in a relatively small all-cash deal that valued the once-publicly-traded company at approximately $34 million (Reuter, 2024).

Despite these commercial challenges, the paediatric approach suggests broader possibilities. Conditions affecting children often involve interventions that benefit from sustained engagement, including attention training, social skills development, and anxiety management. Digital therapeutics designed around how children actually interact with technology may prove more effective than traditional approaches requiring them to adopt adult-oriented treatment formats.

Neurology and Rehabilitation

Recovery from stroke, traumatic brain injury, and other neurological conditions often depends on intensive, repetitive therapeutic exercises, more than the healthcare system can typically provide during scheduled appointments. Patients making good progress in rehabilitation sessions may plateau simply because they cannot access enough therapy hours.

Digital therapeutics for neurological rehabilitation extend treatment beyond clinical walls. Patients continue structured exercises at home, with the software tracking performance and adjusting difficulty to maintain therapeutic challenge. Some programmes incorporate gamification to sustain engagement with inherently repetitive exercises. For patients whose recovery depends on volume of practice, these interventions can mean the difference between partial and more complete restoration of function.

Musculoskeletal Health

Musculoskeletal (MSK) conditions are one of the largest growth areas in digital therapeutics. Chronic back pain, joint disorders, and post-surgical rehabilitation affect hundreds of millions of people worldwide, and traditional treatment often relies on in-person physiotherapy sessions that many patients cannot access frequently enough to achieve optimal outcomes.

Companies such as Hinge Health, Kaia Health, and Sword Health have developed DTx platforms that combine exercise therapy programmes with sensor-based motion tracking, educational content, and health coaching. These platforms guide patients through personalised exercise routines, using smartphone cameras or wearable sensors to monitor form and provide real-time feedback. Clinical studies have demonstrated reductions in pain scores and improvements in physical function comparable to in-person physiotherapy for conditions including chronic low back pain and osteoarthritis.

The MSK DTx market has attracted substantial investment, in part because the target conditions are highly prevalent and costly. Employers and insurers have been particularly receptive, as musculoskeletal conditions are a leading driver of workplace disability and healthcare expenditure. Unlike some DTx categories that have struggled commercially, MSK digital therapeutics have found relatively strong product-market fit by demonstrating measurable reductions in surgery rates, opioid use, and overall musculoskeletal spending.

Table 7.3: FDA-Cleared Digital Therapeutics

*Pear Therapeutics filed for bankruptcy in April 2023 and ceased operations. These products are no longer available. **Akili Interactive was acquired by Virtual Therapeutics in mid-2024 (~$34M all-cash deal).

Prescription Digital Therapeutics

When a physician writes a prescription for a digital therapeutic, something familiar becomes unfamiliar. The prescription pad and the clinical workflow are recognisable, but what follows differs considerably from the pharmacy trip patients expect. Understanding how prescription digital therapeutics (PDTs) integrate into clinical care reveals both their potential and the friction they introduce into established systems.

Prescribing in a World Built for Pills

Electronic health records were designed around medications and procedures, not software activations. When a clinician decides a patient would benefit from a digital therapeutic for insomnia, the EHR must accommodate an order type it may not natively support. Some systems require workarounds, such as ordering the PDT as a referral or using free-text orders that bypass decision support. EHR vendors have begun partnering with digital therapeutic companies to create smoother integrations, but adoption remains uneven. A clinician enthusiastic about prescribing digital therapeutics may find their workflow battles against systems designed for a different era of medicine.

From Prescription to Patient

The patient experience after receiving a PDT prescription differs fundamentally from picking up medication at a pharmacy. Instead of a physical product, patients receive access codes or download links. The "dispensing" happens through app stores or direct web portals. Some companies have built processes modelled on US specialty pharmacies to handle the logistics, contacting patients to guide them through activation. Others rely on patients to navigate the process independently.

This difference matters for adherence. A patient who struggles with the activation process may never begin treatment. One who expects the familiar pharmacy experience may be confused by instructions to download software. Healthcare systems implementing PDTs must consider this journey, because a prescription that never converts to an activated treatment provides no therapeutic benefit.

Visibility Into Treatment

Once patients activate digital therapeutics, something new becomes possible. Clinicians gain visibility into treatment that never existed with take-home therapies: whether the patient actually used the intervention, how many sessions they completed, and how their scores have moved.

Provider dashboards can display engagement metrics and clinical progress, enabling follow-up conversations grounded in data rather than patient recall. A psychiatrist prescribing a digital therapeutic for depression might see that their patient completed eight of twelve modules and showed improving mood scores. Alternatively, they might see the patient stopped engaging after the first week, prompting intervention before the next scheduled appointment. This visibility creates opportunities for more responsive care, though it also requires clinicians to develop new habits of checking dashboards and acting on the data they reveal.

Beyond Standalone Treatment

The most sophisticated implementations position digital therapeutics as components of comprehensive treatment plans. A patient with substance use disorder might receive a digital therapeutic alongside medication-assisted treatment and counselling. A patient with chronic insomnia might use a digital CBT-I programme while their physician addresses contributing medical conditions. The digital therapeutic becomes one element of an orchestrated approach, its effectiveness enhanced by the clinical context surrounding it.

Reimbursement and Market Access

The gap between regulatory approval and commercial viability has proven to be digital therapeutics' most significant challenge. Products with strong clinical evidence and FDA clearance have still failed commercially because they could not achieve sustainable reimbursement. Understanding this gap reveals why the sector has experienced such turbulence despite genuine clinical promise.

The Fundamental Problem: Where Does Software Fit?

Healthcare reimbursement systems evolved around clear categories: drugs dispensed by pharmacies, devices implanted by surgeons, services delivered by clinicians. Digital therapeutics fit awkwardly into all of these and perfectly into none. Is a prescription app a medication, a device, or a service? The answer determines which benefit covers it, which distribution channels apply, and ultimately whether patients can access it affordably.

Payers have responded by experimenting with multiple pathways, each with distinct advantages and limitations.

Navigating the Benefit Categories

Some insurers have chosen to cover digital therapeutics through medical benefits, treating them analogously to medical devices or services. Coverage decisions weigh clinical evidence, cost-effectiveness analyses, and alignment with treatment guidelines. For digital therapeutics that succeed in this pathway, patients access treatment through familiar medical benefit structures with standard cost-sharing.

Others position digital therapeutics within pharmacy benefits, leveraging the existing infrastructure for prescription drug distribution and coverage. Pharmacy benefit managers accustomed to handling medications are developing processes for digital products, though the fit requires adaptation. A prescription for software does not require inventory management or cold chain logistics, but it does require activation codes and download instructions.

Self-insured employers were early adopters through direct contracting arrangements that bypass traditional reimbursement categories entirely. These employers, seeking effective treatments that might reduce overall healthcare costs, can add digital therapeutics to their benefit offerings without waiting for insurers to develop coverage policies. For example, an employer persuaded by the evidence that digital CBT-I reduces insomnia-related healthcare costs might contract directly with a digital therapeutic company, making the treatment available to employees as a covered benefit.

Outcomes-Based Arrangements: Aligning Payment with Value

The digital therapeutic value proposition (measurable, evidence-based outcomes) creates natural opportunities for outcomes-based reimbursement. If a digital therapeutic claims to reduce symptoms by a certain percentage, why not tie payment to achieving that outcome? Risk-sharing arrangements are emerging, with manufacturers accepting some financial risk if their products underperform.

These arrangements align incentives in appealing ways but introduce complexity. Measuring outcomes requires data infrastructure. Defining success requires agreement between manufacturers and payers. Adjudicating whether outcomes were achieved requires processes that add administrative burden. Still, for a sector struggling to demonstrate value in traditional reimbursement frameworks, outcomes-based contracts offer a path forward that exploits digital therapeutics' inherent measurability.

The Commercial Reality Check

The difficulties several pioneering companies have faced, including high-profile bankruptcies, have sobered the entire sector. Regulatory clearance, it turns out, is only the beginning. Companies must also achieve efficient patient acquisition, sustain engagement throughout treatment courses, and generate enough revenue to cover development costs and fund continued operations.

A digital therapeutic might be clinically effective for the patients who receive it while the company behind it fails because too few patients gained access. Germany's DiGA pathway, with its automatic reimbursement for approved products, is one attempt to bridge this gap. Other markets are watching to see whether similar frameworks emerge that might finally align clinical promise with commercial sustainability.

Implementation Considerations

A healthcare organisation deciding to offer digital therapeutics soon discovers that the challenges extend beyond selecting which products to prescribe. Success requires building new capabilities: educating clinicians unfamiliar with these interventions, identifying appropriate patients, sustaining engagement throughout treatment, and integrating new data streams into care workflows.

Preparing Clinicians for a New Treatment Category

Most clinicians completed their training before digital therapeutics existed. They learned to prescribe medications, order imaging, and refer to specialists, but not to evaluate or prescribe software-based treatments. When a digital therapeutic becomes available for a condition they regularly treat, clinicians need more than an announcement; they need education that addresses which patients are appropriate candidates, how the digital therapeutic complements other treatments, and what the evidence actually shows.

Effective implementation programmes combine formal education with clinical decision support embedded in prescribing workflows. A clinician considering treatment for insomnia might see a prompt noting that a digital CBT-I programme is available, with quick access to prescribing criteria and evidence summaries. This just-in-time guidance proves more effective than expecting clinicians to recall details from training sessions completed months earlier.

Matching Patients to Treatments

Not every patient with an appropriate diagnosis is a good candidate for digital therapeutics. The intervention requires sustained engagement with a software application, an ask that some patients cannot or will not fulfil. Successful implementation involves thoughtful patient selection considering condition severity, digital literacy, technology access, and personal preferences.

A patient comfortable with smartphone applications who travels frequently and struggles to attend in-person appointments might be an ideal candidate for a digital therapeutic. Another patient with the same diagnosis who lacks a smartphone, distrusts technology, or prefers face-to-face interaction might do better with traditional treatment. Clinicians developing judgment about patient selection improve outcomes and reduce frustration on both sides of the treatment relationship.

The Engagement Challenge

Here lies perhaps the most important difference between digital therapeutics and traditional medications: a pill works whether or not the patient feels engaged with the treatment experience. A digital therapeutic works only if the patient interacts with it consistently over the full treatment duration.

Dropout rates in digital therapeutic programmes can be extreme without appropriate support: a study of the most popular mental health apps found that they lost more than 80% of users within ten days, with 30-day retention rates typically below 4% (Baumel et al., 2019). This sobering statistic reflects the challenge of sustaining engagement with any self-directed intervention. Patients begin with motivation, encounter barriers or competing demands, and gradually disengage. The therapeutic benefit they might have received disappears along with their engagement.

Successful implementations address engagement deliberately. Design features within the digital therapeutic itself (gamification, progress tracking, personalised feedback) contribute to sustained use. But clinical support matters too. When patients know their provider is monitoring their progress and will follow up, engagement typically improves. Some programmes incorporate human coaching alongside the digital intervention, providing the accountability that helps patients persist through challenging moments.

Using Treatment Data

Digital therapeutics generate data that traditional treatments never provided. Organisations can see not just whether a prescription was filled but whether it was used, for how long, and with what engagement patterns. This visibility enables more responsive care.

Establishing processes for reviewing patient progress data requires workflow changes. Who monitors the dashboards? How frequently? What triggers outreach to a patient showing declining engagement? Organisations that answer these questions thoughtfully can intervene before patients abandon treatment entirely, potentially salvaging therapeutic benefit that would otherwise be lost.

Addressing Technology Access

A treatment requiring a smartphone and internet connectivity excludes patients lacking either. Healthcare organisations committed to equitable care must address these access barriers, whether through device lending programmes, connectivity assistance, or simply acknowledging that digital therapeutics should not be the only treatment option available. The promise of digital therapeutics to expand access must be balanced against the reality that they may inadvertently widen disparities if implementation ignores technology access issues.

Future Directions

The digital therapeutics sector stands at an inflection point. Early pioneers have proven that software can deliver genuine therapeutic benefit; several have also demonstrated that commercial sustainability remains elusive. The next phase of development will likely differ substantially from the first.

Expanding the Therapeutic Frontier

As evidence accumulates, digital therapeutics will address conditions beyond the behavioural health applications that dominated early development. Researchers are investigating applications in oncology supportive care, pain management, and cardiovascular rehabilitation. Each new therapeutic area requires fresh clinical trials and regulatory submissions, but the basic approach of delivering evidence-based interventions through software has been validated. Which conditions will prove amenable to software-based intervention, and which will not, remains an open question.

Convergence with Pharmaceuticals

The future likely holds tighter integration between digital therapeutics and pharmaceutical treatments. Rather than competing, these modalities may increasingly combine. A medication for a psychiatric condition might be paired with a digital therapeutic that delivers behavioural support, with clinical trials validating the combination rather than either component alone. Pharmaceutical companies, with their established reimbursement relationships and distribution capabilities, may become key partners or acquirers of digital therapeutic developers, addressing commercial sustainability challenges through existing infrastructure.

AI-Driven Personalisation

Current digital therapeutics deliver largely standardised interventions, but the same AI capabilities changing other areas of healthcare will reshape this field. Future products may adapt in real-time to individual patient characteristics and responses, intensifying support when patients show signs of disengagement, adjusting difficulty based on performance, and tailoring content to individual preferences and learning styles. Whether this personalisation improves outcomes beyond standardised approaches is an empirical question that remains largely unanswered.

Regulatory and Evidence Evolution

Regulatory frameworks will mature as agencies accumulate experience with digital therapeutics. International harmonisation efforts may eventually reduce the burden of seeking approval in multiple jurisdictions. Evidence standards may evolve too, with real-world data from deployed products supplementing traditional trial evidence. A digital therapeutic used by thousands of patients generates outcome data that can validate or challenge findings from controlled trials.

Industry Restructuring

The commercial difficulties faced by early entrants suggest industry restructuring ahead. Some companies will fail; others will merge or be acquired. Partnerships with established healthcare entities (health systems, insurers, pharmaceutical companies) may prove more viable than standalone digital therapeutic companies. The sector that emerges from this consolidation will likely look quite different from the venture-backed era of early digital therapeutics. What persists will be the core insight that launched the field: software can deliver genuine therapeutic benefit, even if the commercial and organisational models for doing so at scale are still being worked out.

Summary

Digital therapeutics have established that software can deliver measurable therapeutic benefit for specific conditions, with the strongest evidence in insomnia (where digital CBT-I matches therapist-delivered treatment), substance use disorders, and increasingly musculoskeletal health. The regulatory frameworks to evaluate these products are maturing, with Germany's DiGA pathway offering the most complete model linking approval to reimbursement.

Yet the field's commercial difficulties - including the failure of several pioneering companies despite strong clinical evidence - demonstrate that proving a treatment works is not the same as building a sustainable way to deliver it. The gap between regulatory approval and patient access, the challenge of sustaining engagement with self-directed interventions, and the awkward fit of software-based treatments within reimbursement systems designed for drugs and devices remain unresolved. For clinicians, the practical question is not whether digital therapeutics have a role but how to identify the products with robust evidence, the patients most likely to benefit, and the implementation approaches most likely to succeed.